

Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Free
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- The Mark Foundation names 2026 Emerging Leader Award recipients
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care - Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- Minimally invasive surgery lowers survival in cervical cancer, new studies show
- A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers













